Sana Biotechnology faces class action lawsuit
Analysis based on 22 articles · First reported Mar 27, 2025 · Last updated May 13, 2025
The class action lawsuit against Sana Biotechnology is expected to negatively impact its stock price and investor confidence due to allegations of securities fraud. Conversely, Levi & Korsinsky may see increased business and positive market sentiment for its role in representing aggrieved shareholders.
Levi & Korsinsky has filed a class action securities lawsuit against Sana Biotechnology, alleging that the company made false and misleading statements to investors between March 17, 2023, and November 4, 2024. The complaint claims that Sana Biotechnology overstated its financial capacity and the promise of its product candidates, SC291, SC379, and SG299, while concealing the risk of insufficient funds and potential discontinuation of these programs. Investors who suffered losses during this period have until May 20, 2025, to request to be appointed as lead plaintiff in the lawsuit. Joseph E. Levi of Levi & Korsinsky is actively involved in the case.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard